 TEL AVIV, Israel and NEW YORK, March 03, 2022 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT, a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that management will participate in a fireside chat at the 34th Annual Roth Conference being held on March 13 - 15, 2022 as well as at the 32nd Annual Oppenheimer Healthcare Conference taking place on March 15 - 17, 2022. 